New HPI prognostic predictor in diffuse large B-cell lymphoma

In a recent article, researchers explained how a single hemoglobin-platelet index (HPI) based on anemia and thrombocytopenia can be used to predict a patient’s prognosis for diffuse large B-cell lymphoma who has not not otherwise specified (DLBCL NOS).

In the study, they evaluated the utility of HPI in a new validation cohort of 94 patients with DLBCL NOS. As a result, they were able to claim that in the validation cohort, HPI successfully distinguished between progression-free survival (PFS) and overall survival. So, using a larger sample of 160 patients, consisting of the derivation cohort (n=66) and a validation cohort (n=94), they then compared the utility of HPI with markers previously reported prognostic indicators such as the National Comprehensive Center Network-International Prognostic Index (NCCN-IPI), Glasgow Prognostic Score (GPS), and Platelet Albumin (PA) Score.

Accordingly, patients with higher HPI scores had significantly poorer outcomes, and HPI independently predicted the prognosis of DLBCL NOS. For predicting PFS, HPI was more accurate than GPS and nearly as accurate as PA score. Additionally, patients with lymphoma cells stained by immunohistochemistry to be positive for interleukin-6 (IL-6) (75/111 cases) had significantly lower hemoglobin and platelet counts than patients. IL-6 negative cases (36/111 cases), suggesting that IL-6 produced by lymphoma cells is responsible for anemia and thrombocytopenia in DLBCL NOS patients.


Comments are closed.